| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Sr. VP & Chief Medical Officer
1 company
Nathalie Adda last filed a Form 4 in April 2022, as Sr. VP & Chief Medical Officer at ENTA. Nathalie Adda's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Nathalie Adda's trades have earned a strong insider score of 80/100 across 9 rated trades. Over a 12-month horizon, all 9 of those trades were profitable, with an average 12-month return of +37.7%.
At the last filing, the largest reported position was 34,982 shares of ENTA. The ENTA filings lean toward selling, a net 199,160 shares.
Nathalie Adda has 27 Form 4 filings on record from June 2015 to April 2022, all as Sr. VP & Chief Medical Officer at Enanta Pharmaceuticals (ENTA), 2015–2022.
The 94 reported transactions were 43 open-market sales, 23 option exercises, 11 stock awards and 9 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $15.3M.
The largest open-market sale was 83,344 shares of ENTA at an average $71.60 on April 4, 2022, about $6.0M. Twelve months later ENTA was down 47%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 83,344 | $71.60 | $5,967,688.19 | -70.4% | -28.7% | -47.4% | |
| Mar 2, 2022 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 36,820 | $70.20 | $2,584,681.81 | -51.3% | -42.8% | -31.7% | |
| Jan 11, 2022 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 12,536 | $70.13 | $879,149.68 | -27.6% | +4.1% | -28.4% | |
| Dec 1, 2021 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 13,523 | $86.35 | $1,167,689.95 | -29.1% | -17.2% | -47.0% | |
| Nov 1, 2021 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 9,547 | $84.89 | $810,419.02 | -26.2% | -30.1% | -46.8% | |
| Oct 11, 2021 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 17,500 | $70.15 | $1,227,619.63 | -39.4% | -0.3% | -33.4% | |
| Sep 20, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 4,155 | $95.32 | $396,036.11 | - | - | - | |
| Aug 20, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 4,155 | $92.32 | $383,596.16 | -93.1% | - | - | |
| Jul 18, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 5,045 | $124.84 | $629,842.67 | -77.0% | - | - | |
| Jun 18, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 4,155 | $114.85 | $477,222.20 | -53.6% | - | - |